Non-small cell lung cancer (NSCLC) is the most common form of lung cancer and a leading cause of death worldwide. Fortunately, the survival rate for NSCLC patients has been increasing, largely due to advances in targeted molecular and immunotherapies. Somatic mutations

Allogeneic hematopoietic cell transplantation (alloHCT) is used to treat a variety of hematologic malignancies and represents the best chance for cure for many patients with these disorders. The effectiveness of alloHCT relies primarily on graft-versus-tumor (GVT) reactivity facilitated by donor T cells, which

Selectively inhibiting protein function through proteolysis-targeting chimeras (PROTACs) has emerged as a novel cancer therapeutic strategy. PROTACs are small molecules with two active domains that bind to an E3 ubiquitin ligase and a protein of interest, which results in

Mosaic loss of chromosome Y (mLOY) is the most common form of clonal mosaicism and is recurrent in the blood cells of adult males. This chromosome alteration typically increases with age and has

Paraneoplastic syndromes are rare disorders co-occurring with cancer that are not directly related to the local presence of tumor cells, but result from the generation of autoantibodies, cytokines, hormones, or peptides in response to the malignancy.

Microsecretory adenocarcinoma (MSA) is a salivary gland tumor that usually presents as a painless mass in the oral cavity. It was first described in case literature in 2019, with 24 definitive cases reported since its initial description. Of these cases, there is only one known to have arisen outside of the oral cavity; that case arose in the parotid gland. In this case, the authors present histomorphologic,

Non-small-cell lung cancer (NSCLC) is a genetically heterogeneous disease. In approximately 2% of NSCLC cases, the primary oncogenic mutation is a chromosomal rearrangement involving ROS1 (c-ros oncogene 1), where one of many diverse gene partners fuses to the 3’ kinase domain of ROS1 and results in the constitutive activation of the ROS1 receptor tyrosine kinase.

Biocare Medical, a leading provider of innovative, automated immunohistochemistry (IHC) and FISH (Fluorescent in situ hybridization) instrumentation and reagents, announces the acquisition of Empire Genomics, a market leader in molecular biomarkers to aid in cancer research and diagnostics.

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer and a leading cause of death worldwide. Fortunately, the survival rate for NSCLC patients has been increasing, in large part due to advances in targeted molecular and immunotherapies. Somatic mutations and gene fusions that alter the receptor tyrosine kinase (RTK)/RAS/REF pathway are frequent

Paraneoplastic syndromes are rare disorders co-occurring with cancer that are not directly related to the local presence of tumor cells, but result from the generation of autoantibodies, cytokines, hormones, or peptides in response to the malignancy. These syndromes have complex manifestations that can affect multiple organ systems, including the neurological, dermatological, gastrointestinal, endocrine, hematologic, and cardiovascular systems; neurologic presentations are most common.